Quality & complianceOfficial

Denmark flags supply problems for Ceva's Amoxival Vet. 400 mg amoxicillin tablets

🇩🇰 DKMA · Thu 05 Nov 2026

The Danish Medicines Agency expects disruption to the veterinary antibiotic from early November to early December 2026, citing production problems at Ceva Animal Health A/S.

The Danish Medicines Agency (DKMA) has reported current supply difficulties for Amoxival Vet. 400 mg tablets in packs of 10, marketed by Ceva Animal Health A/S. The notice was published on 5 November 2026 in the agency's section on medicine supply announcements.

The product contains the active substance amoxicillin (ATC vet code QJ01CA04). DKMA gives the cause as production problems and the expected period of disruption as the start of November to the start of December 2026.

The notice does not describe any safety concern, and it does not name an alternative product or say how widely availability will be affected. DKMA directs questions about the current status to the company.

Supply notices of this kind are intended to give prescribers and the supply chain advance warning of gaps in availability.

What it means for your team

  • Veterinary prescribers and wholesalers in Denmark should expect limited availability of the 10-tablet pack until around early December 2026.
  • Market-access and supply teams should contact Ceva Animal Health A/S for the latest status, as DKMA refers such queries to the company.
  • The notice cites a manufacturing cause and no safety issue, so it should not need pharmacovigilance follow-up based on the information given.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →